Shares of Genus plc (LON:GNS - Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 2,230.59 ($29.82) and traded as high as GBX 2,655 ($35.50). Genus shares last traded at GBX 2,600 ($34.76), with a volume of 63,300 shares traded.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on GNS shares. Shore Capital reiterated a "buy" rating and issued a GBX 2,900 price target on shares of Genus in a research note on Thursday, September 4th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Genus from GBX 2,550 to GBX 2,900 and gave the company a "buy" rating in a research note on Monday, September 15th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Genus currently has a consensus rating of "Buy" and an average target price of GBX 2,900.
Check Out Our Latest Stock Analysis on GNS
Genus Trading Up 0.2%
The company has a debt-to-equity ratio of 53.12, a current ratio of 1.80 and a quick ratio of 1.08. The firm has a market capitalization of £1.72 billion, a PE ratio of 90.14, a price-to-earnings-growth ratio of 2.87 and a beta of 0.37. The business's 50-day moving average price is GBX 2,569.77 and its 200-day moving average price is GBX 2,230.59.
Genus (LON:GNS - Get Free Report) last announced its earnings results on Thursday, September 4th. The company reported GBX 81.80 earnings per share (EPS) for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. As a group, analysts expect that Genus plc will post 70.9644323 earnings per share for the current fiscal year.
Insider Buying and Selling at Genus
In related news, insider Jorgen Kokke sold 3,450 shares of the stock in a transaction on Thursday, September 25th. The stock was sold at an average price of GBX 2,332, for a total transaction of £80,454. 0.70% of the stock is currently owned by corporate insiders.
Genus Company Profile
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
